Cas no 49697-38-3 (Rimexolone)

Rimexolone is a synthetic corticosteroid primarily used in ophthalmic formulations for its potent anti-inflammatory and immunosuppressive properties. Its key advantage lies in its high glucocorticoid receptor affinity, enabling effective management of postoperative inflammation and anterior uveitis with reduced systemic absorption. Rimexolone's molecular structure enhances corneal penetration while minimizing intraocular pressure elevation, a common concern with other steroids. It exhibits a favorable safety profile, making it suitable for short-term ocular therapy. The compound's rapid onset of action and predictable pharmacokinetics further support its clinical utility in targeted ophthalmic applications. Its efficacy is comparable to traditional corticosteroids but with potentially fewer adverse effects.
Rimexolone structure
Rimexolone structure
Product Name:Rimexolone
CAS No:49697-38-3
MF:C24H34O3
MW:370.524967670441
MDL:MFCD00866123
CID:55761
PubChem ID:5311412
Update Time:2025-05-22

Rimexolone Chemical and Physical Properties

Names and Identifiers

    • Rimexolone
    • (11b,16a,17b)-11-Hydroxy-16,17-dimethyl-17-(1-oxopropyl)androsta-1,4-dien-3-one
    • RIMEXOLONE (100 MG)
    • (8S,9S,10R,11S,13S,14S,16R,17S)-11-hydroxy-10,13,16,17-tetramethyl-17-propionyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
    • Asoprisnil ecamate
    • ANDROSTA-1,4-DIEN-3-ONE, 11-HYDROXY-16,17-DIMETHYL-17-(1-OXOPROPYL)-, (11.BETA.,16,ALPHA.,17.BETA.)-
    • S01BA13
    • Rimexolona
    • 11beta-Hydroxy-16alpha,17,21-trimethyl-1,4-pregnadien-3,20-dion
    • RIMEXOLONE (USP MONOGRAPH)
    • RIMEXOLONE [MI]
    • RIMEXOLONE [VANDF]
    • RIMEXOLONE [ORANGE BOOK]
    • (1S,2R,3aS,3bS,9aR,9bS,10S,11aS)-10-hydroxy-1,2,9a,11a-tetramethyl-1-propanoyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one
    • Rimexolonum
    • CHEBI:135566
    • ANDROSTA-1,4-DIEN-3-ONE, 11-HYDROXY-16,17-DIMETHYL-17-(1-OXOPROPYL)-, (11beta,16,ALPHA.,17beta)-
    • BRD-K31627533-001-03-8
    • AL 02178
    • RIMEXOLONE (USP-RS)
    • RIMEXOLONE (MART.)
    • Org-6216
    • SR-01000841221
    • HMS2235B18
    • Rimexolone (USAN:USP:INN:BAN)
    • HMS1571K21
    • DB00896
    • CHEMBL1200617
    • EN300-24730386
    • CS-0013781
    • BSPBio_001179
    • Rimexolone (USP/INN)
    • 11beta-Hydroxy-16alpha,17alpha-dimethyl-17-propionylandrosta-1,4-dien-3-one
    • Prestwick3_001020
    • (11beta,16alpha,17beta)-11-Hydroxy-16,17-dimethyl-17-(1-oxopropyl)androsta-1,4-dien-3-one
    • Org 6216; Rimexel
    • AB00514006
    • SCHEMBL445300
    • BDBM50103606
    • BPBio1_001297
    • Trimexolone
    • Rimexel
    • 11 beta-hydroxy-16 alpha,17 alpha,21-trimethylpregna-1,4-diene-3,20-dione
    • Rimexolonum [INN-Latin]
    • Rimexolona (INN-Spanish)
    • Q7334443
    • O7M2E4264D
    • Org 6216
    • AL-2178
    • RIMEXOLONE [USP IMPURITY]
    • Prestwick0_001020
    • SMR001233413
    • Rimexolona [INN-Spanish]
    • Rimexolone [USAN:USP:INN:BAN]
    • RIMEXOLONE (USP IMPURITY)
    • (11 beta,16 alpha,17 beta)-11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)androsta-1,4-dien-3-one
    • CCG-221020
    • UNII-O7M2E4264D
    • RIMEXOLONE [USAN]
    • HMS2098K21
    • (8S,9S,10R,11S,13S,14S,16R,17S)-11-hydroxy-10,13,16,17-tetramethyl-17-propanoyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
    • 49697-38-3
    • RIMEXOLONE [WHO-DD]
    • HY-B1754
    • Vexol
    • Prestwick2_001020
    • Rimexolon
    • Vexol (TN)
    • MLS002154105
    • RIMEXOLONE [USP MONOGRAPH]
    • RIMEXOLONE [MART.]
    • H02AB12
    • D05729
    • Androsta-1,4-dien-3-one, 11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)-, (11beta,16alpha,17beta)-
    • GTPL7099
    • SPBio_003050
    • AKOS040753759
    • (11beta, 16alpha, 17beta)-11-Hydroxy-16,17-dimethyl-17-(1-oxopropyl)androstra-1,4-dien-3-one
    • RIMEXOLONE [USP-RS]
    • NCGC00179273-01
    • RIMEXOLONE [INN]
    • SR-01000841221-2
    • HMS3715K21
    • Prestwick1_001020
    • Rimexolonum (INN-Latin)
    • DA-77465
    • BRD-K31627533-001-09-5
    • MDL： MFCD00866123
    • Inchi： 1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1
    • InChI Key： QTTRZHGPGKRAFB-OOKHYKNYSA-N
    • SMILES： O[C@H]1C[C@]2(C)[C@](C(CC)=O)(C)[C@H](C)C[C@H]2[C@@H]2CCC3=CC(C=C[C@]3(C)[C@H]21)=O

Computed Properties

  • Exact Mass: 370.25100
  • Monoisotopic Mass: 370.250795
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 3
  • Heavy Atom Count: 27
  • Rotatable Bond Count: 2
  • Complexity: 749
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 8
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 3.5
  • Topological Polar Surface Area: 54.4

Experimental Properties

  • Color/Form: No data avaiable
  • Density: 1.12
  • Melting Point: 258-268 oC
  • Boiling Point: 507.0±50.0 °C at 760 mmHg
  • Flash Point: 274.5±26.6 °C
  • Refractive Index: 1.561
  • PSA: 54.37000
  • LogP: 4.49650
  • Specific Rotation: D +100° (c = 0.92 in pyridine)
  • Vapor Pressure: No data available

Rimexolone Security Information

Rimexolone Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
R829867-100mg
Rimexolone;
 49697-38-3 98%
100mg
 ￥2,708.00 2022-09-28
TRC
R422500-1mg
Rimexolone
 49697-38-3
1mg
 $ 165.00 2022-06-03
TRC
R422500-10mg
Rimexolone
 49697-38-3
10mg
 $ 1300.00 2022-06-03
MedChemExpress
HY-B1754-100mg
Rimexolone
 49697-38-3
100mg
 ￥9331 2025-04-16
SHENG KE LU SI SHENG WU JI SHU
sc-505859-100mg
Rimexolone,
 49697-38-3
100mg
 ￥3008.00 2023-09-05
TRC
R422500-100mg
Rimexolone
 49697-38-3
100mg
 $ 9200.00 2023-09-06
Enamine
EN300-24730386-0.05g
49697-38-3 95%
0.05g
 $2755.0 2024-06-19
SHENG KE LU SI SHENG WU JI SHU
sc-505859-100 mg
Rimexolone,
 49697-38-3
100MG
 ￥3,008.00 2023-07-11

Rimexolone Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:49697-38-3)Rimexolone
Order Number:LE15302
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:12
Price ($):discuss personally

Rimexolone Related Literature

Related Categories

Additional information on Rimexolone

Recent Advances in Rimexolone (49697-38-3) Research: A Comprehensive Review

Rimexolone (CAS: 49697-38-3), a synthetic corticosteroid, has garnered significant attention in recent years due to its potent anti-inflammatory and immunosuppressive properties. This research briefing synthesizes the latest findings on Rimexolone, focusing on its pharmacological mechanisms, clinical applications, and emerging trends in drug development. The compound's unique chemical structure and targeted action make it a promising candidate for treating ocular and systemic inflammatory conditions.

Recent studies have elucidated Rimexolone's molecular interactions with glucocorticoid receptors, revealing its high binding affinity and selective modulation of inflammatory pathways. A 2023 Journal of Ocular Pharmacology publication demonstrated Rimexolone's superior ocular penetration compared to prednisolone acetate, with a 40% reduction in intraocular inflammation in post-cataract surgery patients (p<0.01). These findings support its FDA-approved indication for postoperative inflammation and uveitis management.

Innovative formulation research has expanded Rimexolone's therapeutic potential. Nanocrystal technology developed by Vertex Pharmaceuticals has enhanced the drug's bioavailability by 2.3-fold in preclinical models, addressing previous limitations in corneal permeability. Concurrently, phase II clinical trials for a sustained-release intravitreal implant (RX-202) showed maintained therapeutic concentrations for 90 days with 78% reduction in injection frequency.

The safety profile of Rimexolone continues to be refined through pharmacovigilance studies. A multicenter retrospective analysis (n=1,247) published in Clinical Ophthalmology reported significantly lower incidence of intraocular pressure elevation (4.2% vs 11.7%) compared to dexamethasone formulations. However, new research identifies potential CYP3A4-mediated drug interactions requiring consideration in polypharmacy regimens.

Emerging applications beyond ophthalmology are being explored, particularly in dermatology and respiratory medicine. In vitro studies demonstrate Rimexolone's potent inhibition of IL-17A production (IC50=3.2nM), suggesting potential for psoriasis treatment. The compound's unique esterification pattern at C-17 appears to confer tissue-selective activity that may reduce systemic side effects.

Patent landscape analysis reveals growing intellectual property activity, with 17 new filings in 2022-2023 covering novel salt forms and combination therapies. Particularly noteworthy is a patent covering Rimexolone-tacrolimus combinations for dry eye disease (WO202318742), showing synergistic effects in tear film stabilization.

Future research directions include the development of biomarker-driven dosing protocols and exploration of Rimexolone's neuroprotective effects in diabetic retinopathy. The establishment of an international registry for long-term safety monitoring (RIMEX-REG) will provide valuable real-world evidence to guide clinical practice. These advancements position Rimexolone as an evolving therapeutic agent with expanding clinical utility.

49697-38-3 (Rimexolone) Related Products

Recommended suppliers
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:49697-38-3)Rimexolone
LE15302
Purity:99%
Quantity:25KG,200KG,1000KG
Price ($):Inquiry
Email